China still bright for Big Pharma


Last summer's dust up between GlaxoSmithKline (GSK) and Chinese regulators over accusations of corruption has quietly subsided. Drug firms perceive the China market has returned to its "business as unusual."

Glaxo responded to the matter by replacing its sales targets for individual reps with broader performance-rating criteria such as improved patient care.

Although far from assured, other members of Big Pharma don't expect the authorities to rattle their sabers again any time soon.

Analysts expect the nation's drug market to continue its annual 15% growth rate and emerge as the globe's second largest pharmaceutical market behind the U.S. by 2016 on the basis of $165B in sales.

(SNY) (LLY) (NVS) (AZN) (PFE) (BMY) (JNJ) (BAYRY) (RHHBY) (NVO) (ABBV)

From other sites
Comments (3)
  • ritam2001
    , contributor
    Comments (406) | Send Message
     
    Add SVA to the mix...hidden gem.
    2 Apr 2014, 11:49 AM Reply Like
  • tomdgascop
    , contributor
    Comments (96) | Send Message
     
    SVA......?
    Last Price
    $
    7.23
    Day Change
    -0.18 | -2.43 % As of Wed 04/02/2014 12:35 PM EST | USD
    Open Price
    $ 7.47
    Day Range
    7.17-7.47
    52-Week Range
    3.16-8.14
    Yield

    Market Cap
    400.6 mil
    Volume
    103,209
    Avg Vol.
    482,549
    Forward P/E
    425.3
    Price/Book
    3.4
    Price/Sales
    5.9
    Price/Cash Flow
    -63.3
    2 Apr 2014, 12:44 PM Reply Like
  • alkmaar
    , contributor
    Comments (30) | Send Message
     
    With a large population in China, big pharmas have great potential there.
    3 Apr 2014, 01:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs